Recent research has demonstrated that successful simultaneous treatment of multiple risk factors including cholesterol, triglycerides, homocysteine, lipoprotein (a) [Lp(a)], fibrinogen, antioxidants, endothelial dysfunction, inflammation, infection, and dietary factors can lead to the regression of coronary artery disease and the recovery of viable myocardium. However, preliminary work revealed that a number of individuals enrolled in the original study went on popular high-protein diets in an effort to lose weight. Despite increasing numbers of individuals following high-protein diets, little or no infor mation is currently available regarding the effect of these diets on coronary artery disease and coronary blood flow.
Twenty-six people were studied for 1 year by using myocardial perfusion imaging (MPI), echocardiography (ECHO), and serial blood work to evaluate the extent of changes in regional coronary blood flow, regional wall motion abnormalities, and several independent variables known to be important in the development and progression of coronary artery disease. Treatment was based on homocysteine, Lp (a), C-reactive protein (C-RP), triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, and fibrinogen levels. Each variable was independently treated as previously reported. MPI and ECHO were performed at the beginning and end of the study for each individual. The 16 people (treatment group/TG) studied modified their dietary intake as instructed. Ten additional individuals elected a different dietary regimen consisting of a "high-protein" (high protein group/HPG) diet, which they believed would "improve" their overall health.
Patients in the TG demonstrated a reduction in each of the independent variables studied with regression in both the extent and severity of coronary artery disease (CAD) as quantitatively measured by MPI. Recovery of viable myocardium was seen in 43.75% of myocardial segments in these patients, documented with both MPI and ECHO evalu ations. Individuals in the HPG showed worsening of their independent variables. Most notably, fibrinogen, Lp (a), and C-RP increased by an average of 14%, 106%, and 61% respectively. Progression of the extent and severity of CAD was documented in each of the vascular territories with an overall cumulative progression of 39.7%. The differences between progression and extension of disease in the HPG and the regression of disease in the TG were statistically (p < 0.001) significant.
Patients following recommended treatment for each of the independent variables were able to regress both the extent and severity of their coronary artery disease (CAD), as well as improve their myocardial wall motion (function) while following the prescribed medical and dietary guidelines. However, individuals receiving the same medical treatment but following a high-protein diet showed a worsening of independent risk factors, in addition to progression of CAD. These results would suggest that high-protein diets may precipitate progression of CAI) through increases in lipid deposition and inflammatory and coagulation pathways.
Get full access to this article
View all access options for this article.
References
1.
Fleming RM: The clinical importance of risk factor modification: Looking at both myocardial viability (MV) and myocardial perfusion imaging (MPI). Int J Angiol9:65-69, 2000.
2.
Fleming RM: The pathogenesis of vascular disease. In: Textbook of Angiology , ed. by Chang JC.New York: Springer-Verlag, 1999, pp 787-798.
3.
Fleming RM: Determining the outcome of risk factor modification using positron emission tomography (PET) imaging. Fourth World Congress International College of Angiology, June 29, 1998, Lisbon, Portugal.
4.
Stary HC: Evolution of atherosclerotic plaques in the coronary arteries of young adults . Arteriosclerosis2:471a, 1983.
Fleming RM, Ketchum K., Fleming DM: Treating hyperlipidemia in the elderly. Angiology46:1075-1083, 1995.
7.
Fleming RM, Ketchum K., Fleming DM: Assessing the independent effect of dietary counseling and hypolipidemic medications on serum lipids. Angiology47:831-840, 1996.
8.
Fleming RM: How to Bypass Your Bypass: What Your Doctor Doesn't Tell You About Cholesterol and Your Diet. Bethel, CT: Rutledge Books, Inc, 1997.
9.
McMurray MP, Cerqueira MT, Connor SL, et al: Changes in lipid and lipoprotein levels and body weight in Tarahumara Indians after consumption of an affluent diet. N Engl J Med325:1704-1708, 1991.
10.
Staab ME, Simari RD, Srivatsa SS, et al: Enhanced angiogenesis and unfavorable remodeling in injured porcine coronary artery lesions: Effects of local basic fibroblast growth factor delivery. Angiology48 :753-760, 1997.
11.
Plotnick GD , Corretti MC, Vogel RA: Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA278:1682-1686, 1997.
12.
Newman WP, Freedman DS, Voor AW, et al: Relationship of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med314:138, 1986.
13.
Prasad K., Kalra J.: Oxygen free radicals and hypercholesterolemic atherosclerosis: Effect of vitamin E. Am Heart J125:958-973, 1993.
14.
McCully KS, Wilson RB: Homocysteine theory of arteriosclerosis. Atherosclerosis22:215-227, 1975.
15.
Verhoef P., Hennekens CH, Malinow MR, et al: A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke25:1924-1930, 1994 .
16.
Alfthan G., Pekkanen J., Jauhianen M., et al: Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population-based study . Atherosclerosis106:9-19, 1994.
17.
Selhub J., Jacques PF, Bostom AG, et al: Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med332:286-291, 1995.
18.
Perry U., Refsum H., Morris RW, et al: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet346:1395-1398, 1995.
19.
Jacobsen DW , Savon SR, Stewart RW, et al: Limited capacity for homocysteine catabolism in vascular cells and tissues: A pathophysiologic mechanism for arterial damage in hyperhomocysteinemia. Circulation92 (suppl) :104, 1995.
20.
Tasi J.-C, Perella MA, Yoshizumi M., et al: Promotion of vascular smooth muscle growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA91:6369-6373, 1994.
21.
Lentz SR, Sobey CG, Piegors DJ, et al: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia . J Clin Invest98:24-29, 1996.
22.
Parthasarathy S.: Oxidation of low-density lipoproteins by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta917:337-340, 1987.
23.
Olszewski AJ , McCully K.: Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med14:683-693, 1993.
24.
Pancharuniti N., Lewis CA, Sauberlich HE, et al: Plasma homocyst(e), folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr59:940-948, 1994.
25.
Mayer EM, Jacobsen DW, Robinson K.: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol27:517-527, 1996.
26.
Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA277 :1775-1781, 1997.
27.
Tawakol A., Omland T., Gerhard M., et al: Hyperhomocysteinemia is associated with impaired endothelial-dependent vasodilation in humans. Circulation95:1191-1121, 1997.
28.
Kottke Marchant K., Green R., Jacobsen DW, et al: High plasma homocysteine: A risk factor for arterial and venous thrombosis in patients with normal hypercoagulation profiles. Clin Appl Thromb Hemost (in press).
29.
Fleming RM, Harrington GM: Quantitative coronary arteriography and it's assessment of atherosclerosis. Part 1. Examining the independent variables. Angiology45:829-833, 1994.
30.
Fleming RM, Harrington GM: Quantitative coronary arteriography and it's assessment of atherosclerosis. Part 2. Calculating stenosis flow reserve directly from percent diameter stenosis . Angiology45:835-840, 1994.
31.
Eaton DL, Fless GM, Kohn WJ: Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA84:3224, 1987.
32.
Elwood PC, Yarnell JW, Pickering J., et al: Exercise, fibrinogen, and other risk factors for ischaemic heart disease. Caerphilly Prospective Heart Disease Study. Br Heart J69:183-187, 1993.
33.
Rauramaa R. , Salonen JT, Kukkonen-Harjula K., et al: Effects of mild physical exercise on serum lipoproteins and metabolites of arachidonic acid: A controlled randomised trial in middle-aged men. Br Med J288:603-606, 1984.
34.
Stephens NG , Parsons A., Schofield PM, et al: Randomized controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS) . Lancet347:781-786, 1996.
35.
Kushi LH, Folsom AR, Prineas RJ, et al: Dietary antioxidants vitamins and death from coronary artery disease in postmenopausal women. N Engl J Med334:1156-1162, 1996.
36.
Kardinaal AF , Kok FJ, Ringstad J., et al: Antioxidants in adipose tissue and risk of myocardial infarction: The EURAMIC Study. Lancet342:1379-1384, 1993.
37.
Rimm EB, Stampfer MJ, Ascherio A., et al: vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med328:1450-1456, 1993 .
38.
Gotto AM, Gorry GA, Thompson JR, et al: Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. Circulation56:875-883, 1977.
39.
Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med334:1150-1155, 1996.
40.
Baker DE, Campbell RK: Vitamin and mineral supplementation in patients with diabetes mellitus . Diabetes Educ18:420-427, 1992.
41.
Prasad K., Gupta JB, Kalra J., et al: Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model. J Mol Cell Cardiol28:375-385, 1996.
42.
Kushi LH, Folsom AR, Prineas RJ, et al: Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med334:1156-1162, 1996.
43.
Hertog MG, Feskens EJ, Hollman PC, et al: Dietary antioxidant flavonoids and risk of coronary heart disease : The Zutphen Elderly Study. Lancet342:1007-1011, 1993.
44.
Faggiotto A. , Ross R., Harker L.: Studies of hypercholesterolemia in the nonhuman primate I: Changes that lead to fatty streak formation. Arteriosclerosis4:323, 1984.
45.
Faggiotto A. , Ross R.: Studies of hypercholesterolemia in the nonhuman primate II: Fatty streak conversion to fibrous plaque. Arteriosclerosis4:341, 1984.
46.
Hughes SE, Crossman D., Hall PA: Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries. Cardiovasc Res27:1214-1219, 1993.
47.
More RS, Brack MJ, Underwood MJ, et al: Growth factor persistence after vessel wall injury in a rabbit angioplasty model. Am J Cardiol73:1031-1032, 1994.
48.
Fischell TA , Derby D., Tse TM, et al: Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty. A quantitative arteriographic analysis. Circulation78:1323-1334, 1988.
49.
Altstidl R. , Goth C., Lehmkuhl H., et al: Quantitative angiographic analysis of PTCA-induced coronary vasoconstriction in single-vessel coronary artery disease. Angiology48:863-869, 1997.
50.
Brogi E., Wu T., Namiki A., et al: Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation90:649-652, 1994.
51.
Stavri GT, Zachary IC, Baskervill, et al: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Circulation92:11-14, 1995.
52.
Bombardini T., Picano E.: The coronary angiogenetic effect of heparin: Experimental basis and clinical evidence. Angiology48:969-976, 1997.
53.
Little TM, Butler BD: Dibutyryl cAMP effects on thromboxane and leukotriene production in decompression-induced lung injury. Undersea Hyperbaric Med24:185-191, 1997.
54.
Tan RA, Spector SL: Antileukotriene agents: Finding their place in asthma therapy. Contemp Int Med9:46-53, 1997.
55.
O'Byrne PM, Israel E., Drazen JM: Antileukotrienes in the treatment of asthma. Ann Intern Med127 :472-480, 1997.
56.
Muhlestein JB, Hammond EH, Carlquist JF, et al: Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol27:1555-1561, 1996 .
57.
Voie AL: Infections may cause secondary CVD events. Med Trib, Intern & Cardiol Edition, August 14, 1997, p1.
58.
Jancin B.: Antimicrobial prevention of MIs tested in trials. Intern Med News, October1, 1997 , p 8.
59.
Boschert S. : Severe periodontitis worsens diabetes, CAD. Intern Med News, November15, 1997, p 10.
60.
Maass M., Krause E., Engel PM, et al: Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis. Angiology48:699-706, 1997.
61.
Fleming RM: The natural progression of atherosclerosis in an untreated patient with hyperlipidemia: Assessment via cardiac PET. Int J Angiol9:70-73, 2000.
62.
Fleming RM: The importance of physiologic information from cardiac PET and SPECT in assessing coronary artery disease in people with "normal" coronary angiograms . J Nucl Cardiol (accepted for publication 1999) .
63.
Allen S., Dashwood M., Morrison K., et al: Different leukotriene constrictor response in human atherosclerotic coronary arteries. Circulation97:2406-2413, 1998.
64.
Ornish DM, Scherwitz LW, Brown SE, et al: Can lifestyle changes reverse coronary heart disease? Lancet336:129-133, 1990.
65.
Fleming RM: Reversing heart disease in the new millennium. Angiology51:617-629, 2000.
66.
Fleming RM, Rose CH, Feldmann KM: Comparing a high-dose dipyridamole SPECT imaging protocol with dobutamine and exercise stress testing protocols. Part I. Angiology 46:547-556, 1995.
67.
Fleming RM, Feldmann KM, Fleming DM: Comparing a high-dose dipyridamole SPECT imaging protocol with dobutamine and exercise stress testing protocols. Part II: Using high-dose dipyridamole to determine lung-to-heart ratios. Inter J Angiol7:325-328, 1998.
68.
Fleming RM, Feldmann KM, Fleming DM: Comparing a high-dose dipyridamole SPECT imaging protocol with dobutamine and exercise stress testing protocols. Part III: Using dobutamine to determine lung-to-heart ratios, left ventricular dysfunction, and a potential viability marker. Int J Angiol8:22-26, 1999.
69.
Fleming RM: Nuclear cardiology: Its role in the detection and management of coronary artery disease. In: Textbook of Angiology, ed. by Chang JC.New York: Springer-Verlag, 1999, pp 397-406.
70.
Fleming RM: High-dose dipyridamole and gated sestamibi SPECT imaging provide diagnostic resting and stress ejection fractions useful for predicting the extent of coronary artery disease. J Am Coll Cardiol (submitted for publication, 1999).
71.
Fleming RM: A tate-en-tate comparison of ejection fraction and regional wall motion abnormalities as measured by echocardiography and gated sestamibi SPECT. J Am Coll Cardiol (submitted for publication, 1999 ).
72.
Fleming RM, Boyd L., Forster M.: Angina is caused by regional blood flow differences. Proof of a physiologic (not anatomic) narrowing. Joint Session of the European Society-American College of Cardiology, ACC 49th Annual Scientific Sessions, March 12, 2000.
73.
Fleming RM: C-reactive protein and thymus detection may represent a marker for bacterially aggravated atherosclerosis. JAMA (submitted for publication, 2000).
74.
Larosa JC, Gordon A., Muesing R., et al: Effects of high-protein, low-carbohydrate dieting on plasma lipoproteins and body weight. J Am Diet Assoc77:264-270, 1980.
